367-65-7

Basic information

• Product Name: 3,5-BIS(TRIFLUOROMETHYL)-1,2-DIAMINOBENZENE
• Synonyms: 3,5-bis(trifluoroMethyl)benzene-1,2-diaMine;3,5-Bis(trifluoroMethyl)benzene-1,2dianiline;1,2-DIAMINO-3,5-BIS(TRIFLUOROMETHYL)BENZENE;3,5-BIS(TRIFLUOROMETHYL)-1,2-DIAMINOBENZENE;3,5-BIS(TRIFLUOROMETHYL)-1,2-PHENYLENEDIAMINE;3,5-Bis(trifluoromethyl)-1,2-diaminobenzene~1,2-Diamino-3,5-bis(trifluoromethyl)benzene;3,5-Bis(trifluoromethyl)-1,2-diaminobenzene, 97+%;3,5-Bis(trifluoromethyl)phenylene-1,2-diamine
• CAS NO: 367-65-7
• Molecular Formula: C₈H₆F₆N₂
• Molecular Weight: 244.14
• EINECS: -0
• Mol File: 367-65-7.mol
• Article Data: 4

Chemical Properties

• Melting Point: 42-44°C
• Boiling Point: 228.2 °C at 760mmHg
• Flash Point: 98.5 °C
• Appearance: /
• Density: 1.516 g/cm³
• Vapor Pressure: 0.0743mmHg at 25°C
• Refractive Index: 1.467
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 1.72±0.10(Predicted)
• Water Solubility: Insoluble in water.
• BRN: 3344332
• CAS DataBase Reference: 3,5-BIS(TRIFLUOROMETHYL)-1,2-DIAMINOBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-BIS(TRIFLUOROMETHYL)-1,2-DIAMINOBENZENE(367-65-7)
• EPA Substance Registry System: 3,5-BIS(TRIFLUOROMETHYL)-1,2-DIAMINOBENZENE(367-65-7)

Safety Data

• Hazard Codes: T
• Statements: 20/21/22-36/37/38-36
• Safety Statements: 26-36/37/39
• RIDADR: 2811
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 367-65-7(Hazardous Substances Data)

Usage

Uses

It is applied as an active pharmaceutical intermediate.

InChI:InChI=1/C8H6F6N2/c9-7(10,11)3-1-4(8(12,13)14)6(16)5(15)2-3/h1-2H,15-16H2

Upstream product

• 328-74-5 3,5-Bis-(trifluoromethyl)aniline 
• 16143-84-3 (3,5-bis(trifluoromethyl)methyl)acetanilide 
• 7732-18-5 water 
• 654-55-7 2-chloro-1-nitro-3,5-bis-trifluoromethyl-benzene 
• 367-71-5 2,4-bis(trifluoromethyl)aniline 
• 320-21-8 2-nitro-4,6-bis-trifluoromethyl-aniline 

Downstream Products

• 1355991-91-1 (1R,2R)-N₁-(5,7-bis(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)cyclohexane-1,2-diamine 
• 1355991-56-8 (1R,2R)-N₁,N₂-bis(5,7-bis(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)cyclohexane-1,2-diamine 
• 1396396-72-7 tert-butyl 4-(3-((2-amino-3,5-bis(trifluoromethyl)phenyl)amino)-3-oxopropanoyl)piperazine-1-carboxylate 
• 1396396-70-5 tert-butyl 4-(3-((2-amino-3,5-bis(trifluoromethyl)phenyl)amino)-3-oxopropyl)-3-oxopiperazine-1-carboxylate 
• 1396396-64-7 tert-butyl 4-(2-((2-amino-3,5-bis(trifluoromethyl)phenyl)amino)-2-oxoethyl)-3-oxopiperazine-1-carboxylate 
• 1396396-66-9 tert-butyl 3-(2-((2-amino-3,5-bis(trifluoromethyl)phenyl)amino)-2-oxoethyl)azetidine-1-carboxylate 
• 1396396-61-4 C₁₈H₂₁F₆N₃O₃ 
• 1396396-62-5 C₁₈H₂₁F₆N₃O₃ 
• 1396396-59-0 N-(2-amino-3,5-bis(trifluoromethyl)phenyl)-2-(methylthio)acetamide 
• 1396396-53-4 tert-butyl (2-((2-amino-3,5-bis(trifluoromethyl)phenyl)amino)-2-oxoethyl)carbamate 

Relevant articles and documents

Chiral 2-aminobenzimidazole bifunctional organocatalysts: Effect of di-CF3 and TFA on catalytic mechanisms

(S,S)-trans-Cyclohexanediamine-5,7-di-CF3-benzimidazole (3b) was developed as a new chiral bifunctional organocatalyst and successfully applied to Michael addition of diethyl malonate to nitroolefins (up to 99%, 98% ee) under neutral condition.

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.